(Q34317484)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Kynurenines in the CNS: recent advances and new questions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Levente Szalardy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

4

József Toldi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

Ferenc Fülöp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

14 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

64-82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids

20 February 2020

cites work

1 reference

Synthesis and metabolism of L-kynurenine in rat brain

31 March 2020

1 reference

Blood?Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

31 March 2020

1 reference

Quinolinic acid, the inescapable neurotoxin

31 March 2020

1 reference

MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum

31 March 2020

1 reference

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

31 March 2020

1 reference

Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects.

31 March 2020

1 reference

Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites

31 March 2020

1 reference

Tryptophan-derived ultraviolet filter compounds covalently bound to lens proteins are photosensitizers of oxidative damage

31 March 2020

1 reference

Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction.

31 March 2020

1 reference

Kynurenic acid has a dual action on AMPA receptor responses.

31 March 2020

1 reference

The Janus-face kynurenic acid

31 March 2020

1 reference

The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications

31 March 2020

1 reference

Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals

31 March 2020

1 reference

Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35

31 March 2020

1 reference

On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress.

31 March 2020

1 reference

A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.

31 March 2020

1 reference

Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats

31 March 2020

1 reference

Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus

31 March 2020

1 reference

Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils

31 March 2020

1 reference

Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate

31 March 2020

1 reference

7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex

31 March 2020

1 reference

Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration

31 March 2020

1 reference

Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection

31 March 2020

1 reference

Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives

31 March 2020

1 reference

Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists

31 March 2020

1 reference

A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study

31 March 2020

1 reference

Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia

31 March 2020

1 reference

Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.

31 March 2020

1 reference

In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum

31 March 2020

1 reference

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

31 March 2020

1 reference

Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease

31 March 2020

1 reference

Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease

31 March 2020

1 reference

3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims

31 March 2020

1 reference

Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex

31 March 2020

1 reference

Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid

31 March 2020

1 reference

Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases

31 March 2020

1 reference

Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease

31 March 2020

1 reference

1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats.

31 March 2020

1 reference

Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain

31 March 2020

1 reference

Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease

31 March 2020

1 reference

Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease

31 March 2020

1 reference

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

31 March 2020

1 reference

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

31 March 2020

1 reference

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid

31 March 2020

1 reference

Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats

31 March 2020

1 reference

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways

31 March 2020

1 reference

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin

31 March 2020

1 reference

Cerebrospinal fluid glutamate levels in chronic migraine

31 March 2020

1 reference

Platelet and Plasma Levels of Glutamate and Glutamine in Migraine With and Without Aura

31 March 2020

1 reference

Familial hemiplegic migraine

31 March 2020

1 reference

Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1.

31 March 2020

1 reference

Meta-analysis of genome-wide association for migraine in six population-based European cohorts

31 March 2020

1 reference

Genome-wide association study reveals three susceptibility loci for common migraine in the general population

31 March 2020

1 reference

Kynurenines and headache.

31 March 2020

1 reference

Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion

31 March 2020

1 reference

Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives

31 March 2020

1 reference

Kynurenate derivative attenuates the nitroglycerin-induced CamKIIα and CGRP expression changes

31 March 2020

1 reference

Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model

31 March 2020

1 reference

Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid

31 March 2020

1 reference

The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid

31 March 2020

1 reference

l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus.

31 March 2020

1 reference

Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortex

31 March 2020

1 reference

Protective effect of ifenprodil against spreading depression in the mouse entorhinal cortex

31 March 2020

1 reference

Kynurenine is an endothelium-derived relaxing factor produced during inflammation

31 March 2020

1 reference

Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits

31 March 2020

1 reference

Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels

31 March 2020

1 reference

L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase

31 March 2020

1 reference

Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of differen

31 March 2020

1 reference

Is Toxoplasma gondii a causal agent in migraine?

31 March 2020

1 reference

The kynurenine system and immunoregulation

31 March 2020

1 reference

IDO expression in the brain: a double-edged sword

31 March 2020

1 reference

A crucial role for tryptophan catabolism at the host/Candida albicans interface.

31 March 2020

1 reference

Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation

31 March 2020

1 reference

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase

31 March 2020

1 reference

A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation

31 March 2020

1 reference

Inhibition of T cell proliferation by macrophage tryptophan catabolism

31 March 2020

1 reference

Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division

31 March 2020

1 reference

T cell apoptosis by tryptophan catabolism

31 March 2020

1 reference

Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo

31 March 2020

1 reference

The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function

31 March 2020

1 reference

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

31 March 2020

1 reference

Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO

31 March 2020

1 reference

IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis

31 March 2020

1 reference

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

31 March 2020

1 reference

Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells.

31 March 2020

1 reference

Characterization of the kynurenine pathway in human neurons

31 March 2020

1 reference

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice

31 March 2020

1 reference

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

31 March 2020

1 reference

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells

31 March 2020

1 reference

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

31 March 2020

1 reference

Th17 Cells and autoimmune encephalomyelitis (EAE/MS).

31 March 2020

1 reference

Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation

31 March 2020

1 reference

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

31 March 2020

1 reference

Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity

31 March 2020

1 reference

Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis

31 March 2020

1 reference

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

31 March 2020

1 reference

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

31 March 2020

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

31 March 2020

1 reference

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

31 March 2020

1 reference

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

31 March 2020

1 reference

Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis

31 March 2020

1 reference

Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis

31 March 2020

1 reference

Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells.

31 March 2020

1 reference

Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2,3-dioxygenase axis

31 March 2020

1 reference

Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases

31 March 2020

1 reference

Interleukin-2, soluble interleukin-2-receptor, neopterin,l-tryptophan and ?2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis

31 March 2020

1 reference

Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients

31 March 2020

1 reference

Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis

31 March 2020

1 reference

Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients

31 March 2020

1 reference

Kynurenine metabolism in multiple sclerosis.

31 March 2020

1 reference

IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment

31 March 2020

1 reference

Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia

31 March 2020

1 reference

Oligodendrocyte killing by quinolinic acid in vitro

31 March 2020

1 reference

Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils

31 March 2020

1 reference

N-Methyl-D-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat.

31 March 2020

1 reference

Synthesis and pharmacological evaluation of some 4-oxo-quinoline-2-carboxylic acid derivatives as anti-inflammatory and analgesic agents

31 March 2020

1 reference

Expression of functional GPR35 in human iNKT cells

31 March 2020

1 reference

Vitamin D, invariant natural killer T-cells and experimental autoimmune disease

31 March 2020

1 reference

Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation

31 March 2020

1 reference

Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases

31 March 2020

1 reference

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

31 March 2020

1 reference

pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I.

31 March 2020

1 reference

Kynurenines in the mammalian brain: when physiology meets pathology

31 March 2020

1 reference

Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain

31 March 2020

1 reference

Can the USP paddle method be used to represent in-vivo hydrodynamics?

31 March 2020

1 reference

Altered kynurenine metabolism correlates with infarct volume in stroke

31 March 2020

1 reference

The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment.

31 March 2020

1 reference

Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia

31 March 2020

1 reference

Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia

31 March 2020

1 reference

Kynurenine metabolism in Alzheimer's disease

31 March 2020

1 reference

Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease.

31 March 2020

1 reference

Tryptophan degradation and immune activation in Alzheimer's disease.

31 March 2020

1 reference

Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus

31 March 2020

1 reference

A beta 1-42 induces production of quinolinic acid by human macrophages and microglia

31 March 2020

1 reference

The excitotoxin quinolinic acid induces tau phosphorylation in human neurons

31 March 2020

1 reference

Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus.

31 March 2020

1 reference

Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus

31 March 2020

1 reference

Kynurenine pathway abnormalities in Parkinson's disease

31 March 2020

1 reference

Increased neopterin production and tryptophan degradation in advanced Parkinson's disease

31 March 2020

1 reference

Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment

31 March 2020

1 reference

Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway

31 March 2020

1 reference

Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.

31 March 2020

1 reference

Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy

31 March 2020

1 reference

The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.

31 March 2020

1 reference

Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease

31 March 2020

1 reference

Early kynurenergic impairment in Huntington's disease and in a transgenic animal model

31 March 2020

1 reference

Tryptophan metabolism and oxidative stress in patients with Huntington's disease

31 March 2020

1 reference

Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice

31 March 2020

1 reference

The kynurenine pathway and inflammation in amyotrophic lateral sclerosis

31 March 2020

1 reference

Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis

31 March 2020

1 reference

Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis

31 March 2020

1 reference

Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasms

31 March 2020

1 reference

Studies on CSF tryptophan metabolism in infantile spasms

31 March 2020

1 reference

Changes in CSF neurotransmitters in infantile spasms

31 March 2020

1 reference

Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children

31 March 2020

1 reference

Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures

31 March 2020

1 reference

The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of L-kynurenine to kynurenic acid: an in vitro study

31 March 2020

1 reference

Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study

31 March 2020

1 reference

Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus

31 March 2020

1 reference

Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents

31 March 2020

1 reference

A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study : special issue related to kynurenine.

31 March 2020

1 reference

Enhancement of brain kynurenic acid production by anticonvulsants--novel mechanism of antiepileptic activity?

31 March 2020

1 reference

Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain

31 March 2020

1 reference

Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms

31 March 2020

1 reference

The analgesic effects of tryptophan and its metabolites in the rat

31 March 2020

1 reference

Evidence for glutamic acid as a possible neurotransmitter between the mesencephalic nucleus cuneiformis and the medullary nucleus raphe magnus in the lightly anesthetized rat

31 March 2020

1 reference

Relationship of glutamate and aspartate to the periaqueductal gray-raphe magnus projection: analysis using immunocytochemistry and microdialysis

31 March 2020

1 reference

Regulation of striatal serotonin release by the lateral habenula-dorsal raphe pathway in the rat as demonstrated by in vivo microdialysis: role of excitatory amino acids and GABA

31 March 2020

1 reference

Pharmacological manipulation of brain kynurenine metabolism

31 March 2020

1 reference

(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.

31 March 2020

1 reference

Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase

31 March 2020

1 reference

Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase

31 March 2020

1 reference

Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities

31 March 2020

1 reference

4-Halo-3-hydroxyanthranilic acids: Potent competitive inhibitors of 3-hydroxy-anthranilic acid oxygenase in vitro

31 March 2020

1 reference

2-Amino-4-[3'-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase

31 March 2020

1 reference

Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase

31 March 2020

1 reference

A comparative study on the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues.

31 March 2020

1 reference

Crystal structure of the Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity

31 March 2020

1 reference

The Mechanism of Kynurenine Hydrolysis Catalyzed by Kynureninase

31 March 2020

1 reference

Isolation and expression of a cDNA clone encoding human kynureninase

31 March 2020

1 reference

Effects of mitochondria and o-methoxybenzoylalanine on 3-hydroxyanthranilic acid dioxygenase activity and quinolinic acid synthesis

31 March 2020

1 reference

Differential effects of bromination on substrates and inhibitors of kynureninase from Pseudomonas fluorescens

31 March 2020

1 reference

S-aryl cysteine S,S-dioxides as inhibitors of mammalian kynureninase

31 March 2020

1 reference

Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen

31 March 2020

1 reference

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

31 March 2020

1 reference

Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors

31 March 2020

1 reference

Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.

31 March 2020

1 reference

Oren-gedoku-to and its Constituents with Therapeutic Potential in Alzheimer's Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity In Vitro

31 March 2020

1 reference

S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase.

31 March 2020

1 reference

Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives

31 March 2020

1 reference

Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels

31 March 2020

1 reference

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

31 March 2020

1 reference

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase

31 March 2020

1 reference

4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata.

31 March 2020

1 reference

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

31 March 2020

1 reference

Rational design of indoleamine 2,3-dioxygenase inhibitors

31 March 2020

1 reference

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

31 March 2020

1 reference

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

31 March 2020

1 reference

Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast

31 March 2020

1 reference

Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase

31 March 2020

1 reference

Plectosphaeroic acids A, B, and C, indoleamine 2,3-dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina.

31 March 2020

1 reference

The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues

31 March 2020

1 reference

Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A.

31 March 2020

1 reference

Biomimetic synthesis of the IDO inhibitors exiguamine A and B.

31 March 2020

1 reference

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

31 March 2020

1 reference

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

31 March 2020

1 reference

Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.

31 March 2020

1 reference

Placebo-controlled trial of oral laquinimod for multiple sclerosis

31 March 2020

1 reference

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

31 March 2020

1 reference

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

31 March 2020

1 reference

Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease

31 March 2020

1 reference

12 December 2020

Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs

1 reference

12 December 2020

Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus.

1 reference

12 December 2020

Degradation of tryptophan in neurodegenerative disorders

1 reference

12 December 2020

Understanding the roles of the kynurenine pathway in multiple sclerosis progression.

1 reference

12 December 2020

The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway

1 reference

12 December 2020

Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase

1 reference

12 December 2020

Excitatory amino acid receptors in rat locus coeruleus. An extracellular in vitro study

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23237916%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference